ad image

Company Info

Bayer

Bayer

Drug Discovery & Development

Overview

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros.
Bayer
Contributions
18 Contributions1 / 1
Bayer
Strategic Collaboration

Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors

Bayer

PR-M11-20-030Dec 10, 2020
Bayer
M&A

Bayer Acquires AskBio to Broaden Innovation Base in Cell and Gene Therapy

Bayer

PR-M10-20-15Oct 27, 2020
Bayer
CRO

Bayer and Nuvisan Create New Research Unit in Berlin

Bayer

PR-M02-20-NI-013Feb 13, 2020
Bayer
FDA Approval

FDA Approves Bayer's Nubeqa® (darolutamide) for Prostate Cancer

Bayer

PR-M08-19-NI-001Aug 01, 2019
Bayer
M&A

Yellow Wood Partners to Acquire Iconic Dr. Scholl’s™ Brand from Bayer

Bayer

PR-M07-19-NI-065Jul 25, 2019
Bayer
FDA Approval

FDA Approves Bayer's Gadavist® (gadobutrol) Injection as the First and Only Contrast Agent for Use in Cardiac MR for Coronary Artery Disease

Bayer

PR-M07-19-NI-040Jul 16, 2019
Bayer
Announcement

Bayer Supervisory Board Takes Action to Address the Glyphosate Litigation and Welcomes the Appointment of Ken Feinberg as Mediator

Bayer

PR-M07-19-NI-009Jul 05, 2019
Bayer
Collaboration

Bayer and Foundation Medicine Announce Global Collaboration to Develop Next-Generation Sequencing (NGS)-based Companion Diagnostics in Oncology

Bayer

PR-M05-19-NI-078May 29, 2019
Bayer
Investment

Bayer Invests $150 Million to Build New Cell Culture Technology Center in Berkeley to Spur Innovation of Biotech Therapies

Bayer

PR-M05-19-NI-040May 14, 2019
Bayer
Oncology

Bayer Announces Results of Sub-group Analysis for Vitrakvi® (larotrectinib) in Patients with NTRK Gene Fusion-Positive Metastatic Non-small Cell Lung Cancer (NSCLC)

Bayer

PR-M04-19-NI-047Apr 15, 2019
Bayer
Corporate Culture

Bayer Only Life Science Company Named as a Most Reputable Company in Biggest-Ever Corporate Reputation Study in U.S.

Bayer

PR-M04-19-NI-036Apr 10, 2019
Bayer
Oncology

Bayer to Obtain Full Rights to Global Development and Commercialization of Oncology Compounds Vitrakvi® (larotrectinib) and BAY 2731954 (LOXO-195)

Bayer

PR-M02-19-NI-040Feb 19, 2019
Bayer
Veterinary

Bayer Introduces Versatile New Option for Heartworm Prevention and Intestinal Parasite Control

Bayer

PR-M01-19-NI-062Jan 22, 2019
Bayer
Prescribing Information

Bayer Updates Betaseron (interferon beta-1b) Prescribing Information in Accordance with the U.S. Food and Drug Administration's Pregnancy and Lactation Labeling Rule

Bayer

PR-M01-19-NI-004Jan 02, 2019
Bayer
FDA Approval

FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)

Bayer

PR-M11-18-NI-104Nov 29, 2018
Bayer
Partnership

Broad and Bayer Expand Partnership, Launching New Research Effort to Develop Therapies for Heart Failure

Bayer

PR-M07-18-NI-005Jul 02, 2018
Bayer
Collaboration

Bayer and MD Anderson Cancer Center Collaborate to Strengthen Oncology Translational Research and Clinical Development

Bayer

PR-M06-18-NI-022Jun 07, 2018
Bayer
Drug Application

FDA Accepts Larotrectinib New Drug Application and Grants Priority Review

Bayer

PR-M05-18-NI-115May 31, 2018
1 / 1
0 Contributors1 / 0

No authors found

1 / 0